News & Publications
Recent Press Releases
Cyteir Therapeutics Secures $80 Million in Series C Financing to Advance Clinical Trials of Lead RAD51 Program
Cyteir Therapeutics Secures $80 Million in Series C Financing to Advance Clinical Trials [...]
Cyteir Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Cyteir Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference LEXINGTON, [...]
Cyteir Therapeutics Advances Clinical Trial of Lead RAD51 Synthetic Lethality Program in Cancer and Expands Senior Leadership Team
Cyteir Therapeutics Advances Clinical Trial of Lead RAD51 Synthetic Lethality Program in Cancer [...]
Cyteir Therapeutics Secures Additional $40.2 Million in its Series B Financing and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor
Cyteir Therapeutics Secures Additional $40.2 Million in its Series B Financing and Doses [...]
Media Contact
Michele Parisi
1-925-864-5028
[email protected]
Recent Cyteir Publications
AACR 2019
Publications
- Ratiu JJ, Racine JJ, Hasham MG, Wang, Q, Branca J, Chapman HD, Zhu J, Donghia N, Philip V, Schott WH, Wasserfall C, Atkinson MA, Mills KD, Leeth CM, Serreze DV. Genetic and Small Molecule Disruption of the AID/RAD51 Axis Similarly Ptotects Nonobese Diabetic Mice from Type 1 Diabetes through Expansion of Regulatory B Lymphocytes. (2017) Journal of Immunology. June; 198(11): 4255-4267. Doi: 10.4049/jimmunol.1700024. Epub 2017 May 1. PMID: 28461573
Lamont KR, Hasham MG, Donghia NM, Branca J, Chavaree M, Chase B, Breggia A, Hedlund J, Emery I, Cavallo F, Jasin M, Ruter J, Mills KD. Attenuating homologous recombination stimulate an AID-induced antileukemic effect. (2013) Journal of Experimental Medicine. May; 210(5):1021-33.
Hasham MG, Donghia NM, Coffey E, Maynard J, Snow KJ, Ames J, Wilpan RY, He Y, King BL, Mills KD. Widespread genomic breaks generated by activation-induced cytidine deaminase are prevented by homologous recombination. (2010) Nature Immunology. September; 11(9): 820-826.